Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials

Wells, George; Parkash, Ratika; Healey, Jeffrey S.; Talajic, Mario; Arnold, J. Malcolm; Sullivan, Shannon; Peterson, Joan; Yetisir, Elizabeth; Theoret-Patrick, Patricia; Luce, Marilynn; Tang, Anthony S. L.
March 2011
CMAJ: Canadian Medical Association Journal;3/8/2011, Vol. 183 Issue 4, p421
Academic Journal
Background: Studies of cardiac resynchronization therapy in addition to an implantable cardioverter defibrillator in patients with mild to moderate congestive heart failure had not been shown to reduce mortality until the recent RAFT trial (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial). We performed a meta-analysis including the RAFT trial to determine the effect of cardiac resynchronization therapy with or without an implant able defibrillator on mortality. Methods: We searched electronic databases and other sources for reports of randomized trials using a parallel or crossover design. We included studies involving patients with heart failure receiving optimal medical therapy that compared cardiac resynchronization therapy with optimal medical therapy alone, or cardiac resynchronization therapy plus an implantable defibrillator with a standard implantable defibrillator. The primary outcome was mortality. The optimum information size was considered to assess the minimum amount of information required in the literature to reach reliable conclusions about cardiac resynchronization therapy. Results: Of 3071 reports identified, 12 studies (n = 7538) were included in our meta- analysis. Compared with optimal medical therapy alone, cardiac resynchronization therapy plus optimal medical therapy significantly reduced mortality (relative risk [RR] 0.73, 95% confidence interval [CI] 0.62-0.85). Compared with an implantable defibrillator alone, cardiac resynchronization therapy plus an implantable defibrillator significantly reduced mortality (RR 0.83, 95% CI 0.72-0.96). This last finding remained significant among patients with New York Heart Association (NYHA) class I or II disease (RR 0.80, 95% CI 0.67-0.96) but not among those with class III or IV disease (RR 0.84, 95% CI 0.69-1.07). Analysis of the optimum information size showed that the sequential monitoring boundary was crossed, which suggests no need for further clinical trials. Interpretation: The cumulative evidence is now conclusive that the addition of cardiac resynchronization to optimal medical therapy or defibrillator therapy significantly reduces mortality among patients with heart failure.


Related Articles

  • Investigation and management of congestive heart failure. Arroll, Bruce; Doughty, Robert; Andersen, Victoria // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;7/24/2010, Vol. 341 Issue 7765, p190 

    The article discusses the management of congestive heart failure. According to the guidance released by the National Institute for Health and Clinical Excellence, the increasing prevalence of congestive heart failure is a result of people living longer and effective treatment for coronary heart...

  • Adjunctive treatment with eplerenone reduced morbidity and mortality in acute myocardial infarction. Pitt, B.; Remme, W.; Zannad, F. // Evidence Based Medicine;Sep2003, p146 

    The article presents a study that examines the effectiveness of adjunctive treatment with eplerenone in reducing the morbidity and mortality in patients with acute myocardial infarction (MI) and congestive heart failure (CHF). It describes the method of the study which observes 6642 patients,...

  • Therapeutic options for congestive heart failure. Ross, Brendan S.; King, Jeffery M.; Fischer, Richard G. // Drug Topics;2/16/98, Vol. 124 Issue 4, p102 

    Presents information on congestive heart failure (CHF) with reference to its therapeutic options in the United States. Estimation of the amount of Americans who are afflicted with CHF; What have been associated with the increase prevalence and incidence of heart failure; Details on the diagnosis...

  • Evaluation of treatment for congestive heart failure in patients aged 60 years and older using... Jenkinson, Crispin; Jenkinson, Damian // Age & Ageing;Jan1997, Vol. 26 Issue 1, p7 

    Evaluates treatment for congestive heart failure of older patients using generic measures of health status measures. Form 36 (SF-36) and Dartmouth COOP charts; Angiotensin converting enzyme inhibitor treatment; Indication for SF-36 and COOP charts health status measures; Standardized...

  • Treating congestive heart failure. Massin, Edward K. // Cortlandt Forum;1/25/96, Vol. 9 Issue 1, p165 

    Discusses the possible treatments at preventing or controlling congestive heart failure (CHF). Persons who are likely to develop CHF; Symptoms; Prognosis.

  • New beta-blocker shown to cut mortality rate. Alexander, Walter // Drug Topics;12/11/95, Vol. 139 Issue 23, p51 

    Reports on the benefits in congestive heart failure (CHF) patients by treatment with carvedilol, a vasodilating beta-blocker with antioxidant effects. Association of agent with improved mortality, hemodynamic and clinical status; Reduction of risks of worsening CHF; Approval of carvedilol in...

  • CHF: Current strategies, future developments. Rodgers, Katie // Drug Topics;2/21/94, Vol. 138 Issue 4, p20 

    Focuses on the approaches for treating congestive heart failure (CHF). Digoxin; Diuretics; ACE inhibitors; Role of nitrates; Beta-blockers; Use of calcium-channel blockers; Development of CHF treatment; Increased CHF incidence.

  • Ace inhibitor receives go-ahead for patients at risk of CHF. Rodman, Morton J.; Hurley, Mary Lou // RN;Feb94, Vol. 57 Issue 2, p78 

    Reports on the availability of enalapril maleate (Vasotec) to treat patients with asymptomatic left ventricular dysfuntion. Prescription for patients who have no symptoms of congestive heart failure (CHF); Dosage; Side effects.

  • Simple route best for CHF?  // JAMA: Journal of the American Medical Association;2/28/96, Vol. 275 Issue 8, p584 

    Suggests that counseling and education could offer a simple, effective method for reducing readmissions and improving quality of life for patients with congestive heart failure (CHF). Details on a study of CHF patients at the Washington University School of Medicine in St. Louis, Missouri;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics